Eyevensys, a French ophthalmic therapy company located in Paris, has appointed Francesco Sinigaglia as Chairman of the Board of Directors.
Sinigaglia is a senior pharma professional and entrepreneur. He is currently a member of the Executive Board of Dompé, and founder and Chief Operating Officer of Anabasis, a biotech company specialising in the development of innovative therapies for the eye that was acquired by the Dompé Group in 2012.
He has more than 30 years of industry experience in the healthcare sector, in particular at Roche headquarters in Basel, Switzerland. In 2002 he co-founded Bioxell, a biotech company he led for eight years and took to the Zurich stock exchange in 2006.
Sinigaglia joins the Eyevensys Board members Chahra Louafi (Bpifrance Investissement); Cécile Tharaud (Inserm Transfert Initiative); Catherine Boulé (CapDecisif Management); Caroline Boukris (independent); Frank Kalkbrenner (BIVF); and Raffy Kazandjian, who is the company's Chief Executive.
